Short-term exercise training in humans attenuates AMP-activated protein kinase (AMPK) activation during subsequent exercise conducted at the same absolute workload. Short-term 5-aminoimidazole-4-carboxyamide-ribonucleoside (AICAR) administration in rats mimics exercise training on skeletal muscle in terms of increasing insulin sensitivity, mitochondrial enzymes and GLUT-4 content but it is not known whether these adaptations are accompanied by reduced AMPK activation during subsequent exercise. We compared the effect of 10 days of treadmill training (60 min/day) with 10 days of AICAR administration (0.5 mg/g body weight i.p.) on subsequent AMPK activation during 45 min of treadmill exercise in male Sprague-Dawley rats.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase which is involved in maintaining cellular ATP levels by inhibiting ATP consuming pathways and activating ATP producing pathways (12) .
AMPK is activated by metabolic-stress that includes muscle contraction, hypoxia, mitochondrial uncoupling, glucose deprivation and also by the pharmacological agents 5-aminoimidazole-4-carboxyamide-ribonucleoside (AICAR), metformin, glitazones and the thienopyridone A769662 (9, 12, 13) .
Increases in skeletal muscle glucose uptake and fat oxidation occur in response to both acute exercise and acute AICAR administration (3, 14, 22) . Likewise, skeletal muscle Glut-4 mRNA and protein levels, hexokinase protein expression, glycogen levels, mitochondrial enzymes and insulin sensitivity are all increased in response to both exercise training and chronic AICAR administration in rats (11, 15-17, 28, 35) . The physiological effects of AICAR appear to be dependent upon AMPK activation in skeletal muscle (18, 23) , however suppression or ablation of AMPK activation only partially attenuates increases in glucose uptake during contraction indicating AMPK is not essential for the response (18, 23) . Furthermore, increases in mitochondrial enzymes and hexokinase expression in response to acute and chronic exercise are essentially normal in mice lacking AMPK, even though AICAR induced increases are abolished in these mice (17, 19) . Thus while AMPK is essential for responses to AICAR treatment it is not essential for glucose uptake during contraction.
We have shown that skeletal muscle AMPK activity is increased ~10-fold during prolonged exercise in untrained humans, yet this increase in AMPK activity during exercise is essentially abolished following 10 days of exercise training (20) . This raises the question as to whether AMPK signaling alone during exercise training is itself sufficient to attenuate the extent of Page 3 of 24 3 AMPK activation during subsequent exercise bouts. In order to investigate this we tested the extent to which daily AICAR treatment could mimic exercise training in reducing the AMPK responsiveness to an exercise challenge. AICAR administration at rest naturally differs to exercise since there is no muscle contraction and there are not the large increases in blood flow or oxygen consumption that occur during exercise/contraction. However, both result in alterations in muscle that signal that there is an energy deficit. Exercise/contraction increases free AMP and reduces creatine phosphate content (20, 32, 33) while AICAR is phosphorylated to 5'-aminoimidazole-4-carboxyamide-ribonucleotide (ZMP) with no apparent changes in skeletal muscle AMP, ATP, ADP or creatine phosphate, (15, 32) .
Therefore, the aim of this study was to determine, in rats, the extent of skeletal muscle AMPK activation during exercise following either 10 days of AICAR administration or 10 days of exercise training. We hypothesized that 10 days of AICAR administration would be insufficient to attenuate skeletal muscle AMPK activation during subsequent exercise.
METHODS

Animals.
This study was approved by the Animal Experimentation Ethics Committee of The University of Melbourne. Male Sprague-Dawley rats (244±3 gr) were housed under controlled temperature (22-23°C) and lighting (12:12 hr light:dark cycle) and were given free access to water and a standard chow diet. Animals were randomly divided into 5 groups: control (CON), acute AICAR, acute exercise, 10 day AICAR treated and 10 day training groups (n=5-8 per group).
These animals were involved in the experiments where AMPK activation was determined. Four Page 4 of 24 4 days prior to the start of the experiment all rats underwent 15 minute periods of running on a treadmill (25 m/min, 8% grade) on two separate days to familiarize the rats to treadmill running.
Experimental procedures
To confirm that AMPK was activated in response to a single injection of AICAR, five rats were subcutaneously injected with a single dose of AICAR (0.5 mg/g body wt; divided among three sites: upper, middle and lower back). Sixty minutes after the AICAR administration rats received an anaesthetic overdose of xylazine HCl (30 mg/kg) and Ketamine HCl (240 mg/kg) followed by cervical dislocation. The 10 day AICAR treated group was injected with AICAR (0.5 mg/g. body wt.) and the other 10 day groups (CON and training) were injected with an equal volume of saline every morning (between 9.00 and 10.00 am.) for 10 days. The 10 days exercise-training group performed treadmill running for 60 min (speed 25 m/min at a 8% grade) each day for 10 days. Body weight and food intake were measured daily.
Twenty-four hr following the treatment, all rats (except the acute AICAR group) received an intraperitoneal injection of 2-deoxy-d-[ 3 H] glucose (2-DG; 50 µCi). CON rats then rested for 45 min on the treadmill whereas the other rats were subjected to 45 min of treadmill running (25 m/min at 8% grade). All rats were then immediately killed as described above. Soleus and extensor digitorum longus (EDL) muscles were rapidly removed and immediately frozen in liquid nitrogen for later determination of AMPK Thr 172 phosphorylation and ACC Ser 218 phosphorylation, muscle glycogen and 2-DG into muscle. After conducting the main study two further groups were utilized for determination of muscle glycogen at rest after 10 days of AICAR administration and at rest after 10 days of exercise training (n=8 per group). Technology, Hartsfordshire, England). Binding was detected with IRDye™ 800-conjugated antirabbit IgG (Rockland, Gilbertsville, PA) secondary antibody. Direct fluorescence was detected and quantified using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NB).
Membranes were then stripped (2% SDS (w/v) in 25mM Glycine, pH 2.0) and re-probed with IRDye™ 800-labeled streptavidin (Rockland, Gilbertsville, PA) and anti-phospho-AMPK Thr 172 antibody (Upstate Biotechnology, New York, NY). Phosphorylation was expressed relative to protein abundance.
Glycogen analysis:
Frozen muscle samples were extracted in 250 µl of 2M HCl at 95°C for 2 h and then neutralized with 750 µl of 0.667 M NaOH.. The extract was then analyzed for glucosyl units using an enzymatic, flurometric assay as previously described (25) .
Page 6 of 24 6 2-Deoxy-D-glucose uptake: Muscle 2-DG uptake was assessed on portions of soleus and EDL muscles in an identical fashion to that described by Campbell and Febbraio (6) . Briefly, the muscle was weighed then digested using NaOH and HCl. One portion of the digest was then deproteinized using Ba(OH) 2 and ZnSO 4 and the other portion was deproteinized using perchloric acid and then spun. Each respective supernatant was then added to water and scintillant and the radioactivity of both treatments was measured using a -counter. The first treatment yields unphosphorylated 2-DG, and the second treatment measures total 2-DG, therefore, the difference gives phosphorylated 2-DG (6).
Statistics:
Results were analyzed by the SPSS statistical package using two-factor repeatedmeasures ANOVA (between factor: treatment; within factor: time) for food intake and body weight. All other results were analyzed using a one-factor ANOVA. If the ANOVA revealed a significant interaction, specific differences between mean values were located using the Fisher's least significance difference test. The level of significance was set at P < 0.05.
RESULTS
Body weight and food intake:
During the 10 day treatment period, all groups increased body weight (BW: CON increased by 95.1 ± 3.5 g, Acute Ex: 87.1 ± 6.0 g, 10 days AICAR: 65.5 ± 3.2 g and 10 days Training: 70.1 ± 4.8 g, respectively). However, the increase in BW was significantly lower for the 10 days AICAR group compared with the other 3 groups (P<0.05). There was no difference in the increase in body weights between CON, acute Ex and 10 days Training. The 10 days training group appeared to have a smaller increase in body weight than CON but this was not significant (P=0.19). Food intake (FI) in 10 days AICAR was significantly (P<0.05) lower than CON and 10 25.6 ± 0.9 g/day). There was no difference in food intake between CON and Acute Ex.
AMPK signaling:
Soleus: Acute AICAR administration had no significant affect on AMPK Thr Fig 3A) . Ten days of exercise training significantly increased resting muscle glycogen levels compared with CON (CON vs No ex after 10 d training; Fig 3A) , and this may be why muscle glycogen content at the end of exercise was not significantly decreased compared with control (CON vs Ex after 10 d training; Fig 3A) . Ten days of AICAR treatment tended to increase resting muscle glycogen levels, however, this was not statistically significant (CON vs No ex after 10 d AICAR; Fig 3A) .
EDL: Only acute exercise significantly (P<0.05) decreased muscle glycogen content compared with CON ( Fig 3B) . Muscle glycogen content after acute exercise was also lower than in the acute AICAR, exercise after 10 days AICAR and no exercise after 10 days AICAR groups. Ten days of Ex Training prevented a significant decrease in muscle glycogen content compared with control, despite 10 days of exercise training not increasing resting muscle glycogen content ( Fig   3B) .
Glucose uptake:
Although glucose uptake tended to increase during an acute exercise bout this was not significant (Figure 4 ). Glucose uptake increased significantly during exercise after 10 days of AICAR treatment and 10 days of exercise training.
DISCUSSION
Acute exercise activated AMPK signaling in the rat soleus muscle and 10 days of exercise training greatly suppressed this exercise-induced increase in AMPK signaling (AMPK Thr 172 phosphorylation and ACC Ser 218 phosphorylation). These findings in the rat are consistent with Page 9 of 24 9 our previous findings in humans (20) . Although 10 days of AICAR administration substantially attenuated the exercise-induced activation of AMPK signaling during exercise in the soleus, ACC Ser 218 phosphorylation was not reduced to the same extent as in the trained rats. Thus, 10 days of exercise training is more effective in attenuating the extent of activation of AMPK during exercise than 10 days of AICAR administration.
As was the case in our previous human study (20) , we found that 10 days of exercise training in rats greatly attenuated the extent of skeletal muscle AMPK activation during exercise (Figure 1 ).
Soleus muscle AMPK Thr 172 phosphorylation and ACC Ser 218 phosphorylation increased during treadmill running but after 10 days of exercise training there was no significant increase in these during subsequent exercise challenge (Figure 1 ). Less activation of AMPK during exercise after short-term exercise training would be expected due to better matching of ATP production to ATP use and therefore attenuated increases in free AMP during contraction/exercise after exercise training (8, 20) . Surprisingly, Durante et al. (11) found that although red quadricep AMPK was activated less during treadmill exercise after 7 wk of exercise training in rats, soleus AMPK activation was not reduced during exercise after training. Compared to the present study, the exercise training intensity and duration used by Durante et al. (11) was greater and the experimental exercise bouts were shorter but more intense, and these differences may have accounted for the different results in the two studies.
In the present study only one daily dose of AICAR was used for the chronic AICAR treatment (0.5 mg/g body wt i.p.). It is therefore possible that a higher daily dose of AICAR (eg 1 mg/g) could be as effective as exercise training in attenuating that activation of AMPK during exercise.
However, we think that this is unlikely since in the soleus the acute AICAR administration increased ACC Ser 218 phosphorylation similarly to the acute exercise bout ( Figure 1B) . In Page 10 of 24 addition, muscle glycogen breakdown was similar in response to acute exercise and acute AICAR administration ( Figure 3A ).
It will be important to now examine the mechanisms whereby 10 days of AICAR treatment attenuates the increase in AMPK activation during exercise. It is possible that there may have been an attenuation of the increase in skeletal muscle free AMP during exercise following 10 days of AICAR treatment. Previously we found that short-term exercise training attenuates the increase in skeletal muscle free AMP in response to subsequent exercise in human biopsy samples (20) . Unfortunately, it was not possible to assess this in the current study because of the time to dissect the muscle such measures unreliable. It is also possible that the higher preexercise muscle glycogen content in the soleus after 10 days of exercise training may have contributed to the attenuated activation of AMPK during exercise after training. Skeletal muscle AMPK activity increases less during contractions in perfused rat soleus muscles (10) and during exercise in humans (36) when begun with high muscle glycogen levels compared with low muscle glycogen levels. However, although AMPK binds to glycogen, addition of glycogen to purified rat liver AMPK does not directly alter AMPK activity (29) Furthermore we have shown that the short-term training effect on the extent of AMPK activation persists independently of pre-exercise muscle glycogen content in humans (20) . Finally, it has been shown that the enzyme that dephosphorylates AMPK, PP2C, is responsible for the decrease in skeletal muscle AMPK activity due to TNF (31) . It is possible that exercise training and AICAR treatment increase PP2C activity and/or expression and that this results in lower levels of AMPK phosphorylation during exercise due to greater AMPK dephosphorylation. However, to date this concept has not been examined.
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Unlike exercise which predominately activates AMPK in slow-twitch muscles (30), AICAR activates AMPK to a greater extent in fast-twitch muscle (1, 2, 18) . Indeed, we found that acute AICAR administration greatly increased AMPK Thr 172 phosphorylation in the EDL muscle ( Figure 2 ) but acute AICAR administration had no effect on AMPK Thr 172 phosphorylation in the soleus (Figure 1 ). However, acute AICAR administration increased ACC Ser 218 phosphorylation substantially in both the soleus and the EDL (Figures 1 and 2 ). This could reflect ACC Ser 218 phosphorylation being a more sensitive indicator of AMPK signaling in vivo than AMPK Thr 172 phosphorylation (7, 24, 34) .
Chronic AICAR treatment significantly increases skeletal muscle glycogen content in the gastrocnemius/plantaris and in red and white quadriceps but not in the soleus muscle (15, 35) . In the present study 10 days of AICAR treatment tended to increase muscle glycogen content in the soleus and EDL but these increases were not significant. It seems, therefore, that some muscles respond differently to others in terms of effects of AICAR on muscle glycogen content.
Unlike findings in humans where short-term exercise training attenuates the increase in glucose uptake during exercise (20, 21, 26) , we found that skeletal muscle glucose uptake was actually greater in both soleus and EDL during subsequent exercise after 10 days of training ( Figure 4 ). It appears that this may be a species difference since several other studies have also demonstrated higher skeletal muscle glucose uptake during contraction/exercise in trained than untrained rats.
Ploug et al. (27) found in a hindlimb perfusion study that exercise trained Wistar rats had significantly higher soleus contraction-stimulated glucose uptake than untrained rats. Very similar results were also obtained in a hindlimb perfusion study using obese Zucker rats (5) . In addition, even though skeletal muscle glucose uptake is reduced during easy treadmill exercise in trained rats compared with untrained rats it is greater during more intense treadmill exercise in Page 12 of 24 12 trained than untrained rats (3) . The running in the current study was difficult for the rats and based on previous research examining similar running speeds and grade would have been ~75% VO 2 max (4). We also found that skeletal muscle glucose uptake during exercise was greater after 10 days of AICAR treatment (Figure 4 ). This novel finding suggests that the exercise training like effects of chronic AICAR treatment also extends to glucose uptake during exercise.
Both chronic AICAR treatment and exercise training increased the extent of skeletal muscle glucose uptake in response to the subsequent exercise challenge (Figure 4 ). Since AMPK activation was attenuated by these treatments (Figure 1 ), it suggests that AMPK is not important for skeletal muscle glucose uptake in response to exercise after training. This is not altogether a surprising finding, however, since dissociations between skeletal muscle AMPK activation and glucose uptake during exercise/contraction have been observed in both humans (20) and mice (18) . It will be important to determine what factors are contributing to the augmentation in glucose uptake during exercise after 10 days of training or AICAR administration. It will also be important to examine whether 10 days of AICAR administration increases exercise performance.
In conclusion, 10 days of AICAR administration substantially mimics exercise training of skeletal muscle by attenuating the increases in AMPK activation in response to a subsequent exercise challenge. 
